ArticleFrontiers in aging neuroscience2022
The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies.
Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Not All Microbiomes Reflect Chronic Pain: Evidence from the Urinary Tract in a Case-Control Study.Journal of clinical medicine · 2026Article
- Gut Lachnospiraceae improves white matter injury-related cognitive decline by increasing L-arginine.Cellular & molecular biology letters · 2026Article
- Five-Year Follow-Up of Photobiomodulation in Parkinson's Disease: A Case Series Exploring Clinical Stability and Microbiome Modulation.Journal of clinical medicine · 2026Article
- Identifying microbial biomarkers of neurodegeneration: a comparative study in Alzheimer's and Parkinson's disease.Frontiers in microbiomes · 2026Article
- Barrier-Immune Gating Failure in Gut-Brain Neuroinflammation: A Working Hypothesis and Conceptual Framework.Behavioural neurology · 2026Review
- Shotgun metagenomic analysis reveals taxonomic and functional alterations in the gut microbiome across prodromal and symptomatic Lewy body disease.Frontiers in microbiomes · 2026Article
- Examination of shared gut microbiome signatures in aging and Parkinson's disease.Frontiers in aging neuroscience · 2026Review
- Food-chain spirochetes: a unified hypothesis for Parkinson's disease and dementia risk.Frontiers in aging neuroscience · 2026Article
- CRAmed: a conditional randomization test for high-dimensional mediation analysis in sparse microbiome data.Bioinformatics (Oxford, England) · 2025Article
- Lewy body diseases and the gut.Molecular neurodegeneration · 2025Review
- Exploring the relationship betweenFrontiers in neuroscience · 2025Article
- The microbiota-gut-brain axis in mental and neurodegenerative disorders: opportunities for prevention and intervention.Frontiers in aging neuroscience · 2025Review
- Exploring gut microbiota alterations in Parkinson's disease: insights from a 16S amplicon sequencing Eastern European pilot study.Frontiers in neuroscience · 2025Article
- Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.Frontiers in neuroscience · 2025Article
- Microbiome-based therapeutics for Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.CNS drugs · 2024Article
- High-salt diet induces microbiome dysregulation, neuroinflammation and anxiety in the chronic period after mild repetitive closed head injury in adolescent mice.Brain communications · 2024Article
- Buty and the beast: the complex role of butyrate in Parkinson's disease.Frontiers in pharmacology · 2024Review
- From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Altered gut microbiome (GM) composition has been established in Parkinson's disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies. Objectives: To investigate the temporal stability of GM profiles from PD patients on standard therapies and those initiating device-assisted therapies (DAT) and define multivariate models of disease and progression. Methods: We evaluated validated clinical questionnaires and stool samples from 74 PD patients and 74 household controls (HCs) at 0, 6, and 12 months. Faster or slower disease progression was defined from levodopa equivalence dose and motor severity measures. 19 PD patients initiating Deep Brain Stimulation or Levodopa-Carbidopa Intestinal Gel were separately evaluated at 0, 6, and 12 months post-therapy initiation. Results: Persistent underrepresentation of short-chain fatty-acid-producing bacteria, Conclusion: We present longitudinal GM studies in PD patients, showing persistently altered GM profiles suggestive of a reduced butyrogenic production potential. DATs exerted variable GM influences across the short and longer-term. We found that specific GM profiles combined with dietary factors improved prediction of disease progression in PD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.